AOC Product DS Release Specific Testing

Methods Regulatory Advantages Contact Us FAQ

AOC product DS release testing quantifies oligonucleotide‑to‑antibody ratio, payload distribution, and free oligonucleotide residual. Creative Biogene provides one‑stop services from DS release testing to IND/BLA data packages, designed to align with ICH Q6B (ADC framework) and industry best practices.

Technical Principles & Test Methods

An AOC consists of three parts: a monoclonal antibody, a linker, and a therapeutic oligonucleotide. As with ADCs, the conjugation reaction produces a mixture of species with different payload numbers. The average OAR (oligonucleotide‑to‑antibody ratio) characterizes the overall payload level. OAR directly affects AOC potency and pharmacokinetics – too low a payload results in insufficient gene regulation, while too high a payload may alter antibody targeting or cause unintended immunogenicity.

At a glance – AOC DS release test panel

Test	Method(s)	Typical Information Provided
OAR / DOL (average & distribution)	SEC‑MALS (primary), AEX‑MALS (distribution)	Average OAR, % unconjugated antibody, % OAR1, % OAR2, etc.
Oligonucleotide payload distribution	AEX‑MALS, LC‑MS	Relative abundance of different OAR variants
Free oligonucleotide residual	LC‑MS/MS (high sensitivity), SEC‑UV	Concentration of unconjugated oligonucleotide

OAR / DOL Detection

OAR (oligonucleotide‑to‑antibody ratio) is the core AOC quality parameter, defined as the average number of oligonucleotides per antibody (analogous to ADC’s DAR). OAR directly affects potency and pharmacokinetics – higher OAR (e.g., OAR2 vs. OAR1) can alter tissue distribution and clearance.

SEC‑MALS (primary method): Separates by hydrodynamic volume under non‑denaturing conditions; MALS measures absolute molecular weight without standards. Combined with UV at 280 nm (antibody) and 260 nm (oligonucleotide), OAR is calculated via mass balance. Ideal for preserving siRNA native structure and assessing aggregates.
AEX‑MALS (distribution analysis): Separates by surface charge – higher OAR species carry more negative charge and elute later. Quantifies the relative abundance of different OAR populations. Note: Resolution depends on oligonucleotide length/charge; for short ASO conjugates, SEC‑MALS may be better for average OAR.

Oligonucleotide Payload Distribution

Payload distribution (relative abundance of OAR variants) provides deeper quality control than average OAR alone, reflecting conjugation efficiency and purification effectiveness. Non‑target variants (e.g., naked antibody, high‑payload species) may affect batch consistency and efficacy. AEX‑MALS uniquely resolves different OAR species into distinct peaks, enabling identification and quantification of each variant.

Free Oligonucleotide Residual Detection

Unreacted free oligonucleotide is a process‑related impurity that may cause immunogenicity or off‑target effects and must be strictly controlled.

LC‑MS/MS (high sensitivity): Separates free oligonucleotides and detects trace levels (LOD 0.05‑0.1 ng/mL, LOQ 0.2‑0.5 ng/mL) with high specificity. Also detects derivatives (capped species, incompletely thiolated impurities).
SEC‑UV (routine monitoring): Free oligonucleotides (~5‑20 kDa) elute after AOCs (~150‑170 kDa) on SEC; UV at 260 nm quantifies content. MALS has limited sensitivity for low MW species, so SEC‑UV is preferred for routine use.

Note – Complete testing scope

In addition to the AOC‑specific assays described below, our drug substance release testing includes all universal release tests required by ICH Q6B (sterility, endotoxin, sub‑visible particulates, pH, osmolality, protein concentration, HCP/HCD residuals, etc.). For a full test matrix, please refer to our Drug Substance Release Testing Service page.

Regulatory Basis

Document	Key Requirement
ICH Q6B	Framework for biologics specifications; quality attributes and acceptance criteria based on CQAs. AOCs can reference the ADC framework, covering OAR, payload distribution, and free oligonucleotide residual.
ICH Q2(R1)/ICH Q2(R2)	Analytical procedure validation – specificity, accuracy, precision, linearity, range, robustness.
ICH Q5C	Purity monitoring for AOCs in stability studies.
USP <129>	Purity analysis for recombinant mAbs; AOCs may reference.
USP <1087>	Standard methods for oligonucleotide characterization.
FDA Guidance	CMC considerations for ADCs – AOC CMC strategies may reference the ADC framework.

Advantages

Full coverage of three core quality attributes: OAR/DOL, oligonucleotide payload distribution, and free oligonucleotide residual.
SEC‑MALS + AEX‑MALS dual‑platform orthogonal strategy – absolute molecular weight determination under non‑denaturing conditions; identifies aggregates, fragments, and different OAR populations in a single LC‑MALS run; orthogonal verification of OAR quantitation.
SEC‑MALS OAR quantitation – absolute molecular weight by MALS plus dual‑wavelength UV (280/260 nm) mass balance for precise OAR determination under non‑denaturing conditions.
AEX‑MALS payload distribution analysis – separates OAR variants using oligonucleotide negative charge characteristics; confirms molecular weight of each peak via MALS; provides in‑depth characterization of OAR distribution.
LC‑MS high‑sensitivity free oligonucleotide detection – triple quadrupole MS with MRM detection achieves detection limit of 0.05‑0.1 ng/mL and quantitation limit of 0.2‑0.5 ng/mL, meeting strict impurity control requirements for AOCs.
ICH Q6B full validation – all methods validated per ICH Q2(R1)/Q2(R2) covering specificity, precision, accuracy, linearity, range, and robustness.
Orthogonal strategy – SEC‑MALS + AEX‑MALS + LC‑MS three‑platform orthogonal verification, fully covering AOC critical quality attributes.

Contact Us

For a customized DS release testing strategy, method validation, or IND/BLA submission support for your AOC product, contact Creative Biogene’s technical team.

FAQ

Q1: Are OAR, payload distribution, and free oligonucleotide residual all mandatory for AOC DS release?

A: Yes. OAR is the core indicator of AOC potency and batch consistency. Oligonucleotide payload distribution (relative abundance of different OAR variants) provides more detailed quality control information than average OAR alone. Free oligonucleotide residual is a process‑related impurity that may cause unintended immunogenicity. All three are critical quality attributes affecting AOC safety and efficacy, and specifications should be set per ICH Q6B (referencing ADC framework).

Q2: How to choose between SEC‑MALS and AEX‑MALS for OAR detection?

A: The two methods are complementary. SEC‑MALS is the primary method for OAR quantitation and aggregate/fragment assessment – it measures absolute molecular weight under non‑denaturing conditions and calculates precise OAR via UV dual‑wavelength mass balance. AEX‑MALS separates OAR variants based on charge differences and provides more detailed payload distribution characterization. Creative Biogene’s recommendation: use SEC‑MALS for OAR quantitation and purity assessment in release testing, and AEX‑MALS for in‑depth payload distribution characterization; provide cross‑validation data from both methods for IND submission.

Q3: What is the required detection limit for free oligonucleotide residual?

A: Free oligonucleotide residual levels in AOCs are typically required to be extremely low. Impurities need to be analyzed to a relative abundance level of 0.1% and fully understood. LC‑MS methods achieve detection limits of 0.05‑0.1 ng/mL and quantitation limits of 0.2‑0.5 ng/mL using MRM mode, far exceeding UV detection and meeting the stringent sensitivity requirements for AOC release testing.

Q4: How do SEC‑MALS and AEX‑MALS complement each other in AOC analysis?

A: The two methods are based on different separation principles and provide complementary quality attribute information. SEC‑MALS separates by hydrodynamic volume – it has advantages for aggregate detection but limited resolution for OAR variants. AEX‑MALS separates by charge differences – it resolves different OAR variants into distinct chromatographic peaks but has limited resolution for aggregates. Combined use fully covers AOC critical quality attributes: SEC‑MALS for purity assessment (monomer/aggregate/fragment) and average OAR quantitation; AEX‑MALS for in‑depth payload distribution characterization. A comprehensive quality assessment study demonstrated that using only a single method is insufficient to fully characterize complex AOC formulations; an integrated SEC‑MALS and AEX‑MALS strategy is necessary.

* For research use only. Not intended for any clinical use.

Quick Inquiry